Illumina Inc. (ILU)
Munich
Closed
Oct 8, 2026
Day's Range
238.6552 wk Range
77.53Overview - ILU - Illumina Inc.
Key Statistics
Valuation
Enterprise Value
1.13B
P/E (Trailing)
‪42.92‬
PEG Ratio
‪-5.32‬
EV / EBITDA
‪0.77‬
Profitability
Profit Margin
‪66.08%‬
Operating Margin
‪27.33%‬
Return on Assets
‪12.79%‬
Return on Equity
‪31.21%‬
Ownership
Shares Outstanding
151.00M
Price stats
50-Day Avg
‪194.10‬
200-Day Avg
‪142.40‬
Peers - ILU - Illumina Inc.
Peer Comparison
Compared with companies in Diagnostics & Research listed on Munich.
- ILUMunichIllumina Inc.+66.13%52-week change42.93P/E (Trailing)‪66.08%‬Profit Margin
- 1HMMunichAdaptive Biotechnologies Corporation Common Stock+56.59%52-week change-65.74P/E (Trailing)‪-20.72%‬Profit Margin
- 0MEMunichTwist Bioscience Corporation+85.89%52-week change-126.15P/E (Trailing)‪50.72%‬Profit Margin
- 1K9MunichCareDx, Inc.+75.91%52-week change-133.75P/E (Trailing)‪67.55%‬Profit Margin
- 5GHMunichGuardant Health Inc.+66.74%52-week change-46.63P/E (Trailing)‪64.46%‬Profit Margin
- 04XMunichPersonalis Inc.+64.96%52-week change-15.92P/E (Trailing)‪22.65%‬Profit Margin
- NG9MunichNeoGenomics, Inc.+60.31%52-week change-20.24P/E (Trailing)‪43.21%‬Profit Margin
Profile Summary - ILU - Illumina Inc.
About
Illumina Inc. is a global genomics and life sciences company that develops DNA sequencing and array-based technologies used to analyze genetic variation and biological function. Its products and systems support research, clinical testing, and applied markets across areas such as oncology, inherited and infectious…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
